{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:12:48Z","timestamp":1793236368222,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:00:00Z","timestamp":1346976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1245\/s10434-012-2606-x","type":"journal-article","created":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T13:30:34Z","timestamp":1346938234000},"page":"660-667","source":"Crossref","is-referenced-by-count":77,"title":["What Is the Best Definitive Treatment for Graves\u2019 Disease? A Systematic Review of the Existing Literature"],"prefix":"10.1245","volume":"20","author":[{"given":"Bradley M.","family":"Genovese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem I.","family":"Noureldine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph P.","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,7]]},"reference":[{"key":"2606_CR1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy. Endocr Rev. 2003;24:802\u201335.","journal-title":"Endocr Rev."},{"key":"2606_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ecl.2009.01.009","volume":"38","author":"L Heged\u00fcs","year":"2009","unstructured":"Heged\u00fcs L. Treatment of Graves\u2019 hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am. 2009;38:355\u201371.","journal-title":"Endocrinol Metab Clin North Am."},{"key":"2606_CR3","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1056\/NEJMcp0801880","volume":"358","author":"GA Brent","year":"2008","unstructured":"Brent GA. Clinical practice. Graves\u2019 disease. N Engl J Med. 2008;358:2594\u2013605.","journal-title":"N Engl J Med."},{"key":"2606_CR4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-10-0475","volume":"163","author":"M Abraham-Nordling","year":"2010","unstructured":"Abraham-Nordling M, Wallin G, Tr\u00e4isk F, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol. 2010;163:651\u20137.","journal-title":"Eur J Endocrinol."},{"key":"2606_CR5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM200102153440707","volume":"344","author":"I Klein","year":"2001","unstructured":"Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344:501\u20139.","journal-title":"N Engl J Med."},{"key":"2606_CR6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0889-8529(18)30165-8","volume":"22","author":"HB Burch","year":"1993","unstructured":"Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263\u201377.","journal-title":"Endocrinol Metab Clin North Am."},{"key":"2606_CR7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-11-0299","volume":"165","author":"F Brandt","year":"2011","unstructured":"Brandt F, Green A, Heged\u00fcs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165:491\u20137.","journal-title":"Eur J Endocrinol."},{"key":"2606_CR8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4158\/EP.17.3.456","volume":"17","author":"RS Bahn","year":"2011","unstructured":"Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17:456\u2013520.","journal-title":"Endocr Pract."},{"key":"2606_CR9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","volume":"7","author":"P Vitti","year":"1997","unstructured":"Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369\u201375.","journal-title":"Thyroid."},{"key":"2606_CR10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1365-2265.1998.00554.x","volume":"49","author":"G Benker","year":"1998","unstructured":"Benker G, Reinwein D, Kahaly G, et al. Is there a methimazole dose effect on remission rate in Graves\u2019 disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf). 1998;49:451\u20137.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2606_CR11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.1989.tb01244.x","volume":"31","author":"AJ Hedley","year":"1989","unstructured":"Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves\u2019 disease: long-term follow-up of 434 patients. Scottish Automated Follow-up Register Group. Clin Endocrinol (Oxf). 1989;31:209\u201318.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2606_CR12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","volume":"1","author":"L Wartofsky","year":"1991","unstructured":"Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves\u2019 disease in Europe, Japan, and the United States. Thyroid. 1991;1:129\u201335.","journal-title":"Thyroid."},{"issue":"170\u20139","key":"2606_CR13","first-page":"e171","volume":"209","author":"I Haejin","year":"2009","unstructured":"Haejin I, Pearce EN, Wong AK, Burgess JF, McAneny DB, Rosen JE. Treatment options for Graves disease: a cost-effectiveness analysis. J Am Coll Surg. 2009;209:170\u20139.e171\u20132.","journal-title":"J Am Coll Surg."},{"key":"2606_CR14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1157\/13097376","volume":"26","author":"D Ab\u00f3s","year":"2007","unstructured":"Ab\u00f3s D, Ruiz P, Prats E, et al. [Treatment of Graves-Basedow\u2019s disease with 131I. Assessment of a \u201cmodulated fixed activity\u201d protocol]. Rev Esp Med Nucl. 2007;26:3\u201310.","journal-title":"Rev Esp Med Nucl"},{"key":"2606_CR15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11845-007-0059-1","volume":"176","author":"HI Adamali","year":"2007","unstructured":"Adamali HI, Gibney J, O\u2019Shea D, Casey M, McKenna TJ. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level. Ir J Med Sci. 2007;176:199\u2013203.","journal-title":"Ir J Med Sci."},{"issue":"252","key":"2606_CR16","first-page":"254","volume":"99","author":"A Agarwal","year":"2001","unstructured":"Agarwal A, Mishra SK. Role of surgery in the management of Graves\u2019 disease. J Indian Med Assoc. 2001;99:252, 254\u20136.","journal-title":"J Indian Med Assoc."},{"key":"2606_CR17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1530\/eje.0.1460767","volume":"146","author":"AM Ahmad","year":"2002","unstructured":"Ahmad AM, Ahmad M, Young ET. Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis. Eur J Endocrinol. 2002;146:767\u201375.","journal-title":"Eur J Endocrinol."},{"key":"2606_CR18","first-page":"1049","volume":"23","author":"JM Al-Kaabi","year":"2002","unstructured":"Al-Kaabi JM, Hussein SS, Bukheit CS, Woodhouse NJ, Elshafie OT, Bererhi H. Radioactive iodine in the treatment of Graves\u2019 disease. Saudi Med J. 2002;23:1049\u201353.","journal-title":"Saudi Med J."},{"key":"2606_CR19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1210\/jc.87.3.1073","volume":"87","author":"EK Alexander","year":"2002","unstructured":"Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab. 2002;87:1073\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"2606_CR20","first-page":"225","volume":"28","author":"A Alfadda","year":"2007","unstructured":"Alfadda A, Malabu UH, El-Desouki MI, et al. Treatment of Graves\u2019 hyperthyroidism\u2014prognostic factors for outcome. Saudi Med J. 2007;28:225\u201330.","journal-title":"Saudi Med J."},{"key":"2606_CR21","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1210\/jc.86.8.3611","volume":"86","author":"A Allahabadia","year":"2001","unstructured":"Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism\u2014prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86:3611\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"2606_CR22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/105072502760043486","volume":"12","author":"CS Bal","year":"2002","unstructured":"Bal CS, Kumar A, Pandey RM. A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid. 2002;12:399\u2013405.","journal-title":"Thyroid."},{"key":"2606_CR23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1210\/jc.2009-1655","volume":"95","author":"F Bogazzi","year":"2010","unstructured":"Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves\u2019 disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2010;95:201\u20138.","journal-title":"J Clin Endocrinol Metab."},{"key":"2606_CR24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/thy.2010.0348","volume":"21","author":"DY Chen","year":"2011","unstructured":"Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. Striving for euthyroidism in radioiodine therapy of Graves\u2019 disease: a 12-year prospective, randomized, open-label blinded end point study. Thyroid. 2011;21:647\u201354.","journal-title":"Thyroid."},{"key":"2606_CR25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00268-004-7529-7","volume":"29","author":"SY Chi","year":"2005","unstructured":"Chi SY, Hsei KC, Sheen-Chen SM, Chou FF. A prospective randomized comparison of bilateral subtotal thyroidectomy versus unilateral total and contralateral subtotal thyroidectomy for graves\u2019 disease. World J Surg. 2005;29:160\u20133.","journal-title":"World J Surg."},{"key":"2606_CR26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.14310\/horm.2002.1243","volume":"8","author":"A Collier","year":"2009","unstructured":"Collier A, Ghosh S, Hair M, Malik I, McGarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs. 555\u00a0MBq) in patients with Graves\u2019 disease. Hormones (Athens). 2009;8:273\u20138.","journal-title":"Hormones (Athens)."},{"key":"2606_CR27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00405-009-1174-6","volume":"267","author":"A Digonnet","year":"2010","unstructured":"Digonnet A, Willemse E, Dekeyser C, et al. Near total thyroidectomy is an optimal treatment for Graves\u2019 disease. Eur Arch Otorhinolaryngol. 2010;267:955\u201360.","journal-title":"Eur Arch Otorhinolaryngol."},{"key":"2606_CR28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00259-006-0234-z","volume":"34","author":"S Dunkelmann","year":"2007","unstructured":"Dunkelmann S, Kuenstner H, Nabavi E, Rohde B, Groth P, Schuemichen C. Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves\u2019 disease. Eur J Nucl Med Mol Imaging. 2007;34:228\u201336.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2606_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0038-1625222","volume":"45","author":"S Dunkelmann","year":"2006","unstructured":"Dunkelmann S, Kunstner H, Nabavi E, Eberlein U, Groth P, Schumichen C. Lithium as an adjunct to radioiodine therapy in Graves\u2019 disease for prolonging the intrathyroidal effective half-life of radioiodine. Useful or not? Nuklearmedizin. 2006;45:213\u20138.","journal-title":"Nuklearmedizin."},{"key":"2606_CR30","first-page":"39","volume":"52","author":"EI Efremidou","year":"2009","unstructured":"Efremidou EI, Papageorgiou MS, Liratzopoulos N, Manolas KJ. The efficacy and safety of total thyroidectomy in the management of benign thyroid disease: a review of 932 cases. Can J Surg. 2009;52:39\u201344.","journal-title":"Can J Surg."},{"key":"2606_CR31","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MNM.0b013e3282fda205","volume":"29","author":"SM Refaei El","year":"2008","unstructured":"El Refaei SM, Shawkat W. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves\u2019 hyperthyroidism. Nucl Med Commun. 2008;29:642\u20138.","journal-title":"Nucl Med Commun."},{"key":"2606_CR32","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-2006-924238","volume":"114","author":"SM Eschmann","year":"2006","unstructured":"Eschmann SM, Thelen MH, Dittmann H, Bares R. Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves\u2019 disease: results of a prospective study. Exp Clin Endocrinol Diabetes. 2006;114:222\u20136.","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"2606_CR33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jamcollsurg.2006.02.031","volume":"202","author":"S Gaujoux","year":"2006","unstructured":"Gaujoux S, Leenhardt L, Tresallet C, et al. Extensive thyroidectomy in Graves\u2019 disease. J Am Coll Surg. 2006;202:868\u201373.","journal-title":"J Am Coll Surg."},{"key":"2606_CR34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/thy.2006.0141","volume":"17","author":"S Grodski","year":"2007","unstructured":"Grodski S, Stalberg P, Robinson BG, Delbridge LW. Surgery versus radioiodine therapy as definitive management for graves\u2019 disease: the role of patient preference. Thyroid. 2007;17:157\u201360.","journal-title":"Thyroid."},{"key":"2606_CR35","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/cbr.2005.20.218","volume":"20","author":"M Grosso","year":"2005","unstructured":"Grosso M, Traino A, Boni G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves\u2019 hyperthyroidism. Cancer Biother Radiopharm. 2005;20:218\u201323.","journal-title":"Cancer Biother Radiopharm."},{"key":"2606_CR36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4158\/EP.7.6.438","volume":"7","author":"ST Hao","year":"2001","unstructured":"Hao ST, Reasner CA 2nd, Becker RA. Use of cold iodine in patients with Graves\u2019 disease: observations from a clinical practice. Endocr Pract. 2001;7:438\u201342.","journal-title":"Endocr Pract."},{"key":"2606_CR37","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2967\/jnumed.110.080473","volume":"51","author":"H Hautzel","year":"2010","unstructured":"Hautzel H, Pisar E, Yazdan-Doust N, Schott M, Beu M, Muller HW. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. J Nucl Med. 2010;51:1917\u201322.","journal-title":"J Nucl Med."},{"key":"2606_CR38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.arcmed.2006.09.007","volume":"38","author":"S Hernandez-Jimenez","year":"2007","unstructured":"Hernandez-Jimenez S, Pachon-Burgos A, Aguilar-Salinas CA, et al. Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage. Arch Med Res. 2007;38:185\u20139.","journal-title":"Arch Med Res."},{"key":"2606_CR39","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s002590100621","volume":"28","author":"D Howarth","year":"2001","unstructured":"Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves\u2019 disease: a clinical outcome study. Eur J Nucl Med. 2001;28:1489\u201395.","journal-title":"Eur J Nucl Med."},{"key":"2606_CR40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/eje.1.01924","volume":"153","author":"BE Jensen","year":"2005","unstructured":"Jensen BE, Bonnema SJ, Hegedus L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves\u2019 disease. Eur J Endocrinol. 2005;153:15\u201321.","journal-title":"Eur J Endocrinol."},{"key":"2606_CR41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3413\/nukmed-0087","volume":"47","author":"C Kobe","year":"2008","unstructured":"Kobe C, Eschner W, Sudbrock F, et al. Graves\u2019 disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200\u00a0Gy? Nuklearmedizin. 2008;47:13\u20137.","journal-title":"Nuklearmedizin."},{"key":"2606_CR42","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1007\/s002590100565","volume":"28","author":"C K\u00f6rber","year":"2001","unstructured":"K\u00f6rber C, Schneider P, K\u00f6rber-Hafner N, H\u00e4nscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves\u2019 disease and toxic nodular goitre? Eur J Nucl Med. 2001;28:1360\u20134.","journal-title":"Eur J Nucl Med."},{"key":"2606_CR43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00595-008-4026-x","volume":"40","author":"A Koyuncu","year":"2010","unstructured":"Koyuncu A, Aydin C, Topcu O, Gokce ON, Elagoz S, Dokmetas HS. Could total thyroidectomy become the standard treatment for Graves\u2019 disease? Surg Today. 2010;40:22\u20135.","journal-title":"Surg Today."},{"key":"2606_CR44","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1445-2197.2005.03441.x","volume":"75","author":"CF Ku","year":"2005","unstructured":"Ku CF, Lo CY, Chan WF, Kung AW, Lam KS. Total thyroidectomy replaces subtotal thyroidectomy as the preferred surgical treatment for Graves\u2019 disease. ANZ J Surg. 2005;75:528\u201331.","journal-title":"ANZ J Surg."},{"key":"2606_CR45","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/thy.2005.15.569","volume":"15","author":"G Lal","year":"2005","unstructured":"Lal G, Ituarte P, Kebebew E, Siperstein A, Duh QY, Clark OH. Should total thyroidectomy become the preferred procedure for surgical management of Graves\u2019 disease? Thyroid. 2005;15:569\u201374.","journal-title":"Thyroid."},{"key":"2606_CR46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0028-1102919","volume":"117","author":"MK Leow","year":"2009","unstructured":"Leow MK, Loh KC, Zhu M, Chan SP, Sundram FX. Iodine-131 therapy for hyperthyroidism prescribed by endocrinologist\u2014our preliminary experience. Exp Clin Endocrinol Diabetes. 2009;117:616\u201321.","journal-title":"Exp Clin Endocrinol Diabetes."},{"key":"2606_CR47","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","volume":"88","author":"WD Leslie","year":"2003","unstructured":"Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab. 2003;88:978\u201383.","journal-title":"J Clin Endocrinol Metab."},{"key":"2606_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jss.2010.12.038","volume":"168","author":"J Liu","year":"2011","unstructured":"Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves\u2019 disease. J Surg Res. 2011;168:1\u20134.","journal-title":"J Surg Res."},{"key":"2606_CR49","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1210\/jc.2007-0879","volume":"92","author":"V Markovic","year":"2007","unstructured":"Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves\u2019 disease. J Clin Endocrinol Metab. 2007;92:3547\u201352.","journal-title":"J Clin Endocrinol Metab."},{"key":"2606_CR50","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2265.2004.02152.x","volume":"61","author":"S Metso","year":"2004","unstructured":"Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004;61:641\u20138.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2606_CR51","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1007\/s00268-005-0770-x","volume":"30","author":"P Moreno","year":"2006","unstructured":"Moreno P, Gomez JM, Gomez N, et al. Subtotal thyroidectomy: a reliable method to achieve euthyroidism in Graves\u2019 disease. Prognostic factors. World J Surg. 2006;30:1950\u20136.","journal-title":"Prognostic factors. World J Surg."},{"key":"2606_CR52","first-page":"112","volume":"86","author":"PE Muller","year":"2001","unstructured":"Muller PE, Bein B, Robens E, Bein HS, Spelsberg F. Thyroid surgery according to Enderlen-Hotz or Dunhill: a comparison of two surgical methods for the treatment of Graves\u2019 disease. Int Surg. 2001;86:112\u20136.","journal-title":"Int Surg."},{"key":"2606_CR53","first-page":"40","volume":"47","author":"BI Nonchev","year":"2005","unstructured":"Nonchev BI, Terzieva DD, Dimov RS, Mateva NG, Tsvetkova TZ, Dimitrakov DY. Early hypothyroidism after subtotal thyroidectomy in patients with Graves\u2019 disease\u2014the role of the preoperative conservative treatment and hormonal status. Folia Med (Plovdiv). 2005;47:40\u20135.","journal-title":"Folia Med (Plovdiv)."},{"key":"2606_CR54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2265.2009.03623.x","volume":"72","author":"OE Okosieme","year":"2010","unstructured":"Okosieme OE, Chan D, Price SA, Lazarus JH, Premawardhana LD. The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol (Oxf). 2010;72:122\u20137.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"2606_CR55","first-page":"405","volume":"78","author":"N Palestini","year":"2007","unstructured":"Palestini N, Grivon M, Durando R, Freddi M, Odasso C, Robecchi A. Thyroidectomy for Graves\u2019 hyperthyroidism. Retrospective study of patients\u2019 appreciation. Ann Ital Chir. 2007;78:405\u201312.","journal-title":"Ann Ital Chir."},{"key":"2606_CR56","first-page":"576","volume":"55","author":"S Panareo","year":"2011","unstructured":"Panareo S, Rossi R, Fabbri S, et al. A practical method for the estimation of therapeutic activity in the treatment of Graves\u2019 hyperthyroidism. Q J Nucl Med Mol Imaging. 2011;55:576\u201385.","journal-title":"Q J Nucl Med Mol Imaging."},{"key":"2606_CR57","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-0038-1625316","volume":"43","author":"E Pirnat","year":"2004","unstructured":"Pirnat E, Zaletel K, Gaberscek S, Fidler V, Hojker S. Early changes of thyroid hormone concentrations after (131)I therapy in Graves\u2019 patients pretreated or not with methimazole. Nuklearmedizin. 2004;43:129\u201334.","journal-title":"Nuklearmedizin."},{"key":"2606_CR58","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/01.mnm.0000130242.29692.b2","volume":"25","author":"S Razvi","year":"2004","unstructured":"Razvi S, Basu A, McIntyre EA, Wahid ST, Bartholomew PH, Weaver JU. Low failure rate of fixed administered activity of 400\u00a0MBq 131I with pre-treatment with carbimazole for thyrotoxicosis: the Gateshead Protocol. Nucl Med Commun. 2004;25:675\u201382.","journal-title":"Nucl Med Commun."},{"key":"2606_CR59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF03345702","volume":"32","author":"C Regalbuto","year":"2009","unstructured":"Regalbuto C, Marturano I, Condorelli A, Latina A, Pezzino V. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up. J Endocrinol Invest. 2009;32:134\u20138.","journal-title":"J Endocrinol Invest."},{"key":"2606_CR60","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00259-002-0877-3","volume":"29","author":"MJ Reinhardt","year":"2002","unstructured":"Reinhardt MJ, Brink I, Joe AY, et al. Radioiodine therapy in Graves\u2019 disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002;29:1118\u201324.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2606_CR61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1024\/1023-9332.7.1.20","volume":"7","author":"J Robert","year":"2001","unstructured":"Robert J, Mariethoz S, Pache JC, et al. Short- and long-term results of total vs. subtotal thyroidectomies in the surgical treatment of Graves\u2019 disease. Swiss Surg. 2001;7:20\u20134.","journal-title":"Swiss Surg."},{"key":"2606_CR62","first-page":"603","volume":"53","author":"R Sankar","year":"2005","unstructured":"Sankar R, Sekhri T, Sripathy G, Walia RP, Jain SK. Radioactive iodine therapy in Graves\u2019 hyperthyroidism: a prospective study from a tertiary referral centre in north India. J Assoc Physicians India. 2005;53:603\u20136.","journal-title":"J Assoc Physicians India."},{"key":"2606_CR63","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1089\/1050725041517093","volume":"14","author":"RB Santos","year":"2004","unstructured":"Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves\u2019 disease. Thyroid. 2004;14:525\u201330.","journal-title":"Thyroid."},{"issue":"360\u20131","key":"2606_CR64","first-page":"372","volume":"106","author":"D Sanyal","year":"2008","unstructured":"Sanyal D, Mukhhopadhyay P, Pandit K, et al. Early treatment with low fixed dose (5\u00a0mCi) radioiodine therapy is effective in Indian subjects with Graves\u2019 disease. J Indian Med Assoc. 2008;106:360\u20131, 372.","journal-title":"J Indian Med Assoc."},{"key":"2606_CR65","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03347067","volume":"34","author":"M Schiavo","year":"2011","unstructured":"Schiavo M, Bagnara MC, Calamia I, et al. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves\u2019 disease: need to retarget the radiation committed dose to the thyroid. J Endocrinol Invest. 2011;34:201\u20135.","journal-title":"J Endocrinol Invest."},{"key":"2606_CR66","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0038-1625295","volume":"41","author":"P Schneider","year":"2002","unstructured":"Schneider P, Korber C, Korber-Hafner N, Hanscheid H, Reiners C. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves\u2019 disease? Nuklearmedizin. 2002;41:240\u20134.","journal-title":"Nuklearmedizin."},{"key":"2606_CR67","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/147323000903700235","volume":"37","author":"GM Shi","year":"2009","unstructured":"Shi GM, Xu Q, Zhu CY, Yang YL. Influence of propylthiouracil and methimazole pre-treatment on the outcome of iodine-131 therapy in hyperthyroid patients with Graves\u2019 disease. J Int Med Res. 2009;37:576\u201382.","journal-title":"J Int Med Res."},{"key":"2606_CR68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1507\/endocrj.K07E-013","volume":"55","author":"K Sugino","year":"2008","unstructured":"Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H. Surgical management of Graves\u2019 disease\u201410-year prospective trial at a single institution. Endocr J. 2008;55:161\u20137.","journal-title":"Endocr J."},{"key":"2606_CR69","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1507\/endocrj.50.595","volume":"50","author":"Y Takamura","year":"2003","unstructured":"Takamura Y, Nakano K, Uruno T, et al. Changes in serum TSH receptor antibody (TRAb) values in patients with Graves\u2019 disease after total or subtotal thyroidectomy. Endocr J. 2003;50:595\u2013601.","journal-title":"Endocr J."},{"key":"2606_CR70","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/01.rlu.0000242213.26839.20","volume":"31","author":"V Vijayakumar","year":"2006","unstructured":"Vijayakumar V, Ali S, Nishino T, Nusynowitz M. What influences early hypothyroidism after radioiodine treatment for Graves\u2019 hyperthyroidism? Clin Nucl Med. 2006;31:688\u20139.","journal-title":"Clin Nucl Med."},{"key":"2606_CR71","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00259-006-0092-8","volume":"33","author":"MA Walter","year":"2006","unstructured":"Walter MA, Christ-Crain M, Schindler C, Muller-Brand J, Muller B. Outcome of radioiodine therapy without, on or 3\u00a0days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33:730\u20137.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2606_CR72","first-page":"1528","volume":"123","author":"RF Wang","year":"2010","unstructured":"Wang RF, Tan J, Zhang GZ, Meng ZW, Zheng W. A comparative study of influential factors correlating with early and late hypothyroidism after (131)I therapy for Graves\u2019 disease. Chin Med J (Engl). 2010;123:1528\u20132.","journal-title":"Chin Med J (Engl)."},{"key":"2606_CR73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/105072501300042947","volume":"11","author":"P Werga-Kjellman","year":"2001","unstructured":"Werga-Kjellman P, Zedenius J, Tallstedt L, Traisk F, Lundell G, Wallin G. Surgical treatment of hyperthyroidism: a ten-year experience. Thyroid. 2001;11:187\u201392.","journal-title":"Thyroid."},{"key":"2606_CR74","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00268-009-0337-3","volume":"34","author":"SM Wilhelm","year":"2010","unstructured":"Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves\u2019 disease in the United States. World J Surg. 2010;34:1261\u20134.","journal-title":"World J Surg."},{"key":"2606_CR75","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/01.mnm.0000183795.59097.42","volume":"26","author":"DE Zantut-Wittmann","year":"2005","unstructured":"Zantut-Wittmann DE, Ramos CD, Santos AO, et al. High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves\u2019 disease. Nucl Med Commun. 2005;26:957\u201363.","journal-title":"Nucl Med Commun."},{"key":"2606_CR76","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1007\/s00268-010-0594-1","volume":"34","author":"G Dionigi","year":"2010","unstructured":"Dionigi G, Dionigi R. Standardization of intraoperative neuromonitoring of recurrent laryngeal nerve in thyroid operation: to the editor. World J Surg. 2010;34:2794\u20135.","journal-title":"World J Surg."},{"key":"2606_CR77","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/jsre.2000.5875","volume":"90","author":"TK Palit","year":"2000","unstructured":"Palit TK, Miller CC, Miltenburg DM. The efficacy of thyroidectomy for Graves\u2019 disease: a meta-analysis. J Surg Res. 2000;90:161\u20135.","journal-title":"J Surg Res."},{"key":"2606_CR78","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ijc.2910500611","volume":"50","author":"P Hall","year":"1992","unstructured":"Hall P, Berg G, Bjelkengren G, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer. 1992;50:886\u201390.","journal-title":"Int J Cancer."},{"key":"2606_CR79","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00268-008-9497-9","volume":"32","author":"P St\u00e5lberg","year":"2008","unstructured":"St\u00e5lberg P, Svensson A, Hessman O, Akerstr\u00f6m G, Hellman P. Surgical treatment of Graves\u2019 disease: evidence-based approach. World J Surg. 2008;32:1269\u201377.","journal-title":"World J Surg."},{"key":"2606_CR80","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1007\/s00268-011-1238-9","volume":"35","author":"C Chiapponi","year":"2011","unstructured":"Chiapponi C, Stocker U, Mussack T, Gallwas J, Hallfeldt K, Ladurner R. The surgical treatment of Graves\u2019 disease in children and adolescents. World J Surg. 2011;35:2428\u201331.","journal-title":"World J Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-012-2606-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-012-2606-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T14:05:29Z","timestamp":1562162729000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-012-2606-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,7]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["2606"],"URL":"https:\/\/doi.org\/10.1245\/s10434-012-2606-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,7]]}}}